Targeting the endothelin axis in prostate carcinoma

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Tumor Biology

• Publication date

  2012-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s13277-011-0299-6PMID 22203496
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inverse baseline expression pattern of the NEP/neuropeptides and NFκB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells

  2011cited by this paper
• Identifying novel prostate cancer associated pathways based on integrative microarray data analysis

  2011cited by this paper
• Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC).

  2011cited by this paper
• Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel.

  2010cited by this paper
• Epithelial-mesenchymal transition in ovarian cancer.

  2010cited by this paper
• Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration‐resistant prostate cancer and bone metastases who were pain‐free or mildly symptomatic for pain: a double‐blind, placebo‐controlled, randomized Phase II tria

  2010cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade.

  2009cited by this paper
• Endothelin‐1 enhances the expression of the androgen receptor via activation of the c‐myc pathway in prostate cancer cells

  2009cited by this paper
• Synergistic Induction of Endothelin-1 by Tumor Necrosis Factor α and Interferon γ Is due to Enhanced NF-κB Binding and Histone Acetylation at Specific κB Sites

  2009cited by this paper
• Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone‐refractory prostate cancer

  2008cited by this paper
• The endothelin axis in cancer.

  2008cited by this paper
• A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate Cancer

  2008cited by this paper
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

  2008cited by this paper
• A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer

  2007cited by this paper
• Endothelins and hypoxia-inducible factor in cancer.

  2007cited by this paper
• Immunohistochemical expression of endothelin-1 and endothelin-A and endothelin-B receptors in high-grade prostatic intraepithelial neoplasia and prostate cancer.

  2007cited by this paper
• Targeting Bone Metastasis in Prostate Cancer with Endothelin Receptor Antagonists

  2006cited by this paper
• Basic Mechanisms Responsible for Osteolytic and Osteoblastic Bone Metastases

  2006cited by this paper
• Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer

  2006influential reference
• Endothelin-1 (ET-1) promotes MMP-2 and MMP-9 induction involving the transcription factor NF-kappaB in human osteosarcoma.

  2006cited by this paper
• The endothelin axis in urologic tumors: mechanisms of tumor biology and therapeutic implications

  2006cited by this paper
• Emerging role of the endothelin axis in ovarian tumor progression.

  2005cited by this paper
• Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma

  2005cited by this paper
• Journal of Translational Medicine BioMed Central Review Endothelin receptors as novel targets in tumor therapy

  2004cited by this paper
• Effects of selective endothelin ET(A) receptor antagonists on endothelin-1-induced potentiation of cancer pain.

  2004cited by this paper
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

  2004cited by this paper
• Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial.

  2003cited by this paper
• The endothelin axis: emerging role in cancer

  2003cited by this paper
• Estrogens affect endothelin-1 mRNA expression in LNCaP human prostate carcinoma cells.

  2002cited by this paper
• Expression and Localization of Endothelin Receptors: Implications for the Involvement of Peripheral Glia in Nociception

  2001cited by this paper
• Endothelin‐1 production by prostate cancer cell lines is up‐regulated by factors involved in cancer progression and down‐regulated by androgens

  2001cited by this paper
• Endothelin-1 and metastatic cancer pain.

  2001cited by this paper
• Expression of endothelin receptor a associated with prostate cancer progression.

  2001cited by this paper
• Protein kinase C delta but not PKC epsilon activity is involved in contractile potentiation by endothelin-1 in the porcine coronary artery.

  2000cited by this paper
• ABT-627, an endothelin ET(A) receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain.

  2000cited by this paper
• UPREGULATION OF ENDOTHELIN 1 AND ITS PRECURSOR BY IL-1β, TNF-α, and TGF-β IN THE PC3 HUMAN PROSTATE CANCER CELL LINE

  1999cited by this paper
• Upregulation of endothelin 1 and its precursor by IL-1beta, TNF-alpha, and TGF-beta in the PC3 human prostate cancer cell line.

  1999cited by this paper
• Endothelin-1 Production by Human Synoviocytes

  1998cited by this paper
• Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors

  1996cited by this paper
• Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer.

  1996cited by this paper
• Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

  1995cited by this paper
• Growth regulatory properties of endothelins.

  1993cited by this paper

• Endothelin-axis antagonism enhances tumor perfusion in pancreatic cancer.

  2022cites this paper
• Exploring the Influence of Different Albumin Binders on Molecular Imaging Probe Distribution.

  2021cites this paper
• Diagnostic accuracy of serum endothelin-1 in patients with HCC on top of liver cirrhosis

  2020cites this paper
• Endothelin receptors promote schistosomiasis-induced hepatic fibrosis via splenic B cells

  2020cites this paper
• Mesenchymal Stromal Cells: Emerging Roles in Bone Metastasis

  2018cites this paper
• Rôle de la Tétraspanine Co-029/TSPAN8 dans le processus métastatiquedans le cancer du côlon

  2016cites this paper
• Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis.

  2016cites this paper
• Activation of ETA Receptor by Endothelin-1 Induces Hepatocellular Carcinoma Cell Migration and Invasion via ERK1/2 and AKT Signaling Pathways

  2016cites this paper
• Skeletal complications in cancer patients with bone metastases

  2016cites this paper
• Targeting the Bone Microenvironment in Metastatic Castration-Resistant Prostate Cancer.

  2016cites this paper
• Hypertension and renal toxicity during angiogenesis inhibition : Salt dependency and treatment options

  2016cites this paper
• New therapeutic targets for cancer bone metastasis.

  2015cites this paper
• Incidence and Risk of Hypertension with Ramucirumab in Cancer Patients: A Meta-Analysis of Published Studies

  2015cites this paper
• The efficacy of cetuximab in a tissue-engineered three-dimensional in vitro model of colorectal cancer

  2014cites this paper
• Treatment of Hypertension and Renal Injury Induced by the Angiogenesis Inhibitor Sunitinib: Preclinical Study

  2014cites this paper
• Review of Animal Models of Prostate Cancer Bone Metastasis

  2014cites this paper
• The prognostic value of Smad4 mRNA in patients with prostate cancer

  2014cites this paper
• Overexpression of LAPTM4B-35: A Novel Marker of Poor Prognosis of Prostate Cancer

  2014cites this paper
• Research on tumorigenicity of cinnamaldehyde in melanoma cell lines and its mechanism

  2014cites this paper
• The endothelin axis in head and neck cancer: a promising therapeutic opportunity?

  2014cites this paper
• Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer

  2014cites this paper
• Hypertension During Vascular Endothelial Growth Factor Inhibition: Focus on Nitric Oxide, Endothelin-1, and Oxidative Stress

  2014cites this paper
• Recent advances in bone-targeted therapies of metastatic prostate cancer.

  2014cites this paper
• Aspects of the endothelin system in colorectal cancer

  2014cites this paper
• Clinical significance of NUCB2 mRNA expression in prostate cancer

  2013cites this paper
• Endothelin Receptor Antagonists (ERA) in Hypertension and ChronicKidney Disease: a Rose with Many Thorns

  2013cites this paper
• Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1

  2013cites this paper
• Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer

  2013cites this paper
• Resistance to Castration – Resistance to Drugs

  2013cites this paper
• Clinical significance of NUCB2 mRNA expression in prostate cancer

  2013cites this paper
• Growth Inhibition and Apoptosis Induction of Human Umbilical Vein Endothelial

  2013cites this paper
• Endothelin Receptor Antagonists ( ERA ) in Hypertension and Chronic Kidney Disease : a Rose with Many

  2013cites this paper
• Growth inhibition and apoptosis induction of human umbilical vein endothelial cells by apogossypolone.

  2013cites this paper
• Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer.

  2013cites this paper
• Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer

  2013cites this paper